Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 286

1.

Cannabidiol Is a Novel Modulator of Bacterial Membrane Vesicles.

Kosgodage US, Matewele P, Awamaria B, Kraev I, Warde P, Mastroianni G, Nunn AV, Guy GW, Bell JD, Inal JM, Lange S.

Front Cell Infect Microbiol. 2019 Sep 10;9:324. doi: 10.3389/fcimb.2019.00324. eCollection 2019.

2.

Defining advanced practice in radiation therapy: A feasibility assessment of a new healthcare provider role in Ontario, Canada.

Harnett N, Bak K, Zychla L, Gutierrez E, Warde P.

Radiography (Lond). 2019 Aug;25(3):241-249. doi: 10.1016/j.radi.2019.02.007. Epub 2019 Feb 28.

PMID:
31301782
3.

Detection of Relapse by Low-dose Computed Tomography During Surveillance in Stage I Testicular Germ Cell Tumours.

Chung P, O'Malley ME, Jewett MAS, Bedard PL, Panzarella T, Sturgeon J, Moore MJ, Hamilton R, Hansen AR, Anson-Cartwright L, Gospodarowicz M, Warde P.

Eur Urol Oncol. 2019 Jul;2(4):437-442. doi: 10.1016/j.euo.2018.08.031. Epub 2018 Oct 2.

PMID:
31277780
4.

Optimal Management of High-risk Stage I Nonseminomatous Germ Cell Tumor: Surveillance is the Preferred Option.

Hamilton RJ, Jewett MAS, Warde P, Hansen A.

Eur Urol Focus. 2019 Sep;5(5):702-703. doi: 10.1016/j.euf.2019.05.003. Epub 2019 May 22.

PMID:
31129064
5.

Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance.

Hamilton RJ, Nayan M, Anson-Cartwright L, Atenafu EG, Bedard PL, Hansen A, Chung P, Warde P, Sweet J, O'Malley M, Sturgeon J, Jewett MAS.

J Clin Oncol. 2019 Aug 1;37(22):1919-1926. doi: 10.1200/JCO.18.01250. Epub 2019 Feb 25.

PMID:
30802156
6.

Applying Radiomics to Predict Pathology of Postchemotherapy Retroperitoneal Nodal Masses in Germ Cell Tumors.

Lewin J, Dufort P, Halankar J, O'Malley M, Jewett MAS, Hamilton RJ, Gupta A, Lorenzo A, Traubici J, Nayan M, Leão R, Warde P, Chung P, Anson Cartwright L, Sweet J, Hansen AR, Metser U, Bedard PL.

JCO Clin Cancer Inform. 2018 Dec;2:1-12. doi: 10.1200/CCI.18.00004.

7.

A Phase 1 Pilot Study of Preoperative Radiation Therapy for Prostate Cancer: Long-Term Toxicity and Oncologic Outcomes.

Glicksman R, Sanmamed N, Thoms J, Zlotta AR, Finelli A, van der Kwast T, Sweet J, Jewett M, Klotz LH, Rosewall T, Fleshner NE, Bristow RG, Warde P, Berlin A.

Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):61-66. doi: 10.1016/j.ijrobp.2018.12.054. Epub 2019 Jan 6.

PMID:
30625410
8.

A phase II randomized controlled trial of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy.

Alibhai SMH, Santa Mina D, Ritvo P, Tomlinson G, Sabiston C, Krahn M, Durbano S, Matthew A, Warde P, O'Neill M, Timilshina N, Segal R, Culos-Reed N.

BMC Cancer. 2019 Jan 3;19(1):2. doi: 10.1186/s12885-018-5189-5.

9.

Improving Quality of Radiation Therapy Care Across Ontario using a Community-of-Practice Approach.

Glicksman R, Ang M, Murray E, Simniceanu C, Lockhart E, Gilbert J, Gutierrez E, Warde P.

Pract Radiat Oncol. 2019 Mar;9(2):e242-e248. doi: 10.1016/j.prro.2018.10.017. Epub 2018 Nov 14.

PMID:
30447404
10.

Protocol for a phase III RCT and economic analysis of two exercise delivery methods in men with PC on ADT.

Alibhai SMH, Ritvo P, Santa Mina D, Sabiston C, Krahn M, Tomlinson G, Matthew A, Lukka H, Warde P, Durbano S, O'Neill M, Culos-Reed SN.

BMC Cancer. 2018 Oct 23;18(1):1031. doi: 10.1186/s12885-018-4937-x.

11.

The Clinical Specialist Radiation Therapist (CSRT): A case study exploring the effectiveness of a new advanced practice role in Canada.

Harnett N, Bak K, Lockhart E, Ang M, Zychla L, Gutierrez E, Warde P.

J Med Radiat Sci. 2018 Jun;65(2):86-96. doi: 10.1002/jmrs.281.

12.

Gene expression signatures prognostic for relapse in stage I testicular germ cell tumours.

Lewin J, Soltan Ghoraie L, Bedard PL, Hamilton RJ, Chung P, Moore M, Jewett MAS, Anson-Cartwright L, Virtanen C, Winegarden N, Tsao J, Warde P, Sweet J, Haibe-Kains B, Hansen AR.

BJU Int. 2018 Nov;122(5):814-822. doi: 10.1111/bju.14372. Epub 2018 May 31.

13.

Do radiation oncology outreach clinics affect the use of radiotherapy?

McLaughlin PY, Kong W, de Metz C, Hanna TP, Brundage M, Warde P, Gutierrez E, Mackillop WJ.

Radiother Oncol. 2018 Apr;127(1):143-149. doi: 10.1016/j.radonc.2017.11.014.

PMID:
29478762
14.

Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor.

Leão R, van Agthoven T, Figueiredo A, Jewett MAS, Fadaak K, Sweet J, Ahmad AE, Anson-Cartwright L, Chung P, Hansen A, Warde P, Castelo-Branco P, O'Malley M, Bedard PL, Looijenga LHJ, Hamilton RJ.

J Urol. 2018 Jul;200(1):126-135. doi: 10.1016/j.juro.2018.02.068. Epub 2018 Feb 21.

PMID:
29474847
15.

A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma.

Leão R, Nayan M, Punjani N, Jewett MAS, Fadaak K, Garisto J, Lewin J, Atenafu EG, Sweet J, Anson-Cartwright L, Boström P, Chung P, Warde P, Bedard PL, Bagrodia A, Freifeld Y, Power N, Winquist E, Hamilton RJ.

Eur Urol Focus. 2018 Dec;4(6):995-1001. doi: 10.1016/j.euf.2018.01.015. Epub 2018 Feb 7.

PMID:
29428550
16.

Recommendations for followup of stage I and II seminoma: The Princess Margaret Cancer Centre approach.

Lieng H, Warde P, Bedard P, Hamilton RJ, Hansen AR, Jewett MAS, O'malley M, Sweet J, Chung P.

Can Urol Assoc J. 2018 Feb;12(2):59-66. doi: 10.5489/cuaj.4531. Epub 2017 Dec 1. Review.

17.

Testicular seminoma: Scattered radiation dose to the contralateral testis in the modern era.

Lieng H, Chung P, Lam T, Warde P, Craig T.

Pract Radiat Oncol. 2018 Mar - Apr;8(2):e57-e62. doi: 10.1016/j.prro.2017.10.003. Epub 2018 Jan 3.

PMID:
29306641
18.

Regional Therapy Might Have a Role.

Chung P, Warde P.

Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):511. doi: 10.1016/j.ijrobp.2017.02.010. Epub 2017 Feb 14. No abstract available.

PMID:
29280440
19.

Improving bone health in men with prostate cancer receiving androgen deprivation therapy: Results of a randomized phase 2 trial.

Alibhai SMH, Breunis H, Timilshina N, Hamidi MS, Cheung AM, Tomlinson GA, Manokumar T, Samadi O, Sandoval J, Durbano S, Warde P, Jones JM.

Cancer. 2018 Mar 15;124(6):1132-1140. doi: 10.1002/cncr.31171. Epub 2017 Dec 6.

20.

Impact of Granulocyte-colony Stimulating Factor on Bleomycin-induced Pneumonitis in Chemotherapy-treated Germ Cell Tumors.

Kwan EM, Beck S, Amir E, Jewett MA, Sturgeon JF, Anson-Cartwright L, Chung PW, Warde PR, Moore MJ, Bedard PL, Tran B.

Clin Genitourin Cancer. 2017 Sep 4. pii: S1558-7673(17)30267-7. doi: 10.1016/j.clgc.2017.08.012. [Epub ahead of print]

PMID:
28943331
21.

Best Practice Recommendations for the Retention of Radiotherapy Records.

Lockhart E, Bak K, Schreiner LJ, Hodgson DC, Gutierrez E, Warde P, Sharpe MB.

Clin Oncol (R Coll Radiol). 2017 Nov;29(11):e195-e202. doi: 10.1016/j.clon.2017.06.013. Epub 2017 Aug 12.

PMID:
28811150
22.

Improved outcomes with dose escalation in localized prostate cancer treated with precision image-guided radiotherapy.

Raziee H, Moraes FY, Murgic J, Chua MLK, Pintilie M, Chung P, Ménard C, Bayley A, Gospodarowicz M, Warde P, Craig T, Catton C, Bristow RG, Jaffray DA, Berlin A.

Radiother Oncol. 2017 Jun;123(3):459-465. doi: 10.1016/j.radonc.2017.04.003. Epub 2017 Apr 20.

PMID:
28434799
23.

Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.

Kulkarni GS, Hermanns T, Wei Y, Bhindi B, Satkunasivam R, Athanasopoulos P, Bostrom PJ, Kuk C, Li K, Templeton AJ, Sridhar SS, van der Kwast TH, Chung P, Bristow RG, Milosevic M, Warde P, Fleshner NE, Jewett MAS, Bashir S, Zlotta AR.

J Clin Oncol. 2017 Jul 10;35(20):2299-2305. doi: 10.1200/JCO.2016.69.2327. Epub 2017 Apr 14.

24.

Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer.

Catton CN, Lukka H, Gu CS, Martin JM, Supiot S, Chung PWM, Bauman GS, Bahary JP, Ahmed S, Cheung P, Tai KH, Wu JS, Parliament MB, Tsakiridis T, Corbett TB, Tang C, Dayes IS, Warde P, Craig TK, Julian JA, Levine MN.

J Clin Oncol. 2017 Jun 10;35(17):1884-1890. doi: 10.1200/JCO.2016.71.7397. Epub 2017 Mar 15.

PMID:
28296582
25.

The effect of bowel preparation regime on interfraction rectal filling variation during image guided radiotherapy for prostate cancer.

Hosni A, Rosewall T, Craig T, Kong V, Bayley A, Berlin A, Bristow R, Catton C, Warde P, Chung P.

Radiat Oncol. 2017 Mar 9;12(1):50. doi: 10.1186/s13014-017-0787-y.

26.

Directly Improving the Quality of Radiation Treatment Through Peer Review: A Cross-sectional Analysis of Cancer Centers Across a Provincial Cancer Program.

Rouette J, Gutierrez E, O'Donnell J, Reddeman L, Hart M, Foxcroft S, Mitera G, Warde P, Brundage MD; Cancer Care Ontario Radiation Oncology Program Leads; Pan-Canadian Peer Review Steering Committee.

Int J Radiat Oncol Biol Phys. 2017 Jul 1;98(3):521-529. doi: 10.1016/j.ijrobp.2016.10.017. Epub 2016 Oct 20.

PMID:
28258891
27.

Long-term outcomes of a phase II trial of moderate hypofractionated image-guided intensity modulated radiotherapy (IG-IMRT) for localized prostate cancer.

Lieng H, Pintilie M, Bayley A, Berlin A, Bristow R, Chung P, Gospodarowicz M, Huang R, Ménard C, Warde P, Catton C.

Radiother Oncol. 2017 Jan;122(1):93-98. doi: 10.1016/j.radonc.2016.10.017. Epub 2016 Nov 9.

PMID:
27838147
28.

Chemotherapy treatment decision-making experiences of older adults with cancer, their family members, oncologists and family physicians: a mixed methods study.

Puts MT, Sattar S, McWatters K, Lee K, Kulik M, MacDonald ME, Jang R, Amir E, Krzyzanowska MK, Leighl N, Fitch M, Joshua AM, Warde P, Tourangeau AE, Alibhai SM.

Support Care Cancer. 2017 Mar;25(3):879-886. doi: 10.1007/s00520-016-3476-8. Epub 2016 Nov 9.

29.

Estimating the Impact of Randomised Control Trial Results on Clinical Practice: Results from a Survey and Modelling Study of Androgen Deprivation Therapy plus Radiotherapy for Locally Advanced Prostate Cancer.

South A, Parulekar WR, Sydes MR, Chen BE, Parmar MK, Clarke N, Warde P, Mason M.

Eur Urol Focus. 2016 Aug;2(3):276-283. doi: 10.1016/j.euf.2015.11.004.

30.

The association between institution at orchiectomy and outcomes on active surveillance for clinical stage I germ cell tumours.

Nayan M, Jewett MA, Anson-Cartwright L, Bedard PL, Moore M, Chung P, Warde P, Sweet J, O'Malley M, Hamilton RJ.

Can Urol Assoc J. 2016 May-Jun;10(5-6):204-209.

31.

Effects of long-term androgen deprivation therapy on cognitive function over 36 months in men with prostate cancer.

Alibhai SM, Timilshina N, Duff-Canning S, Breunis H, Tannock IF, Naglie G, Fleshner NE, Krahn MD, Warde P, Marzouk S, Tomlinson GA.

Cancer. 2017 Jan 1;123(2):237-244. doi: 10.1002/cncr.30320. Epub 2016 Sep 1.

32.

Optimizing computed tomography simulation wait times in a busy radiation medicine program.

Roussos J, Zahedi P, Spence T, Swanson LA, Li-Cheung F, Cops F, Darcy P, Chhin V, Moyo E, Warde P, Foxcroft S, Liu FF.

Pract Radiat Oncol. 2017 Jan - Feb;7(1):e77-e83. doi: 10.1016/j.prro.2016.06.007. Epub 2016 Jun 23.

PMID:
27552810
33.

Conditional Risk of Relapse in Surveillance for Clinical Stage I Testicular Cancer.

Nayan M, Jewett MA, Hosni A, Anson-Cartwright L, Bedard PL, Moore M, Hansen AR, Chung P, Warde P, Sweet J, O'Malley M, Atenafu EG, Hamilton RJ.

Eur Urol. 2017 Jan;71(1):120-127. doi: 10.1016/j.eururo.2016.07.013. Epub 2016 Aug 12.

PMID:
27527805
34.

Clinical Characteristics and Outcomes of Late Relapse in Stage I Testicular Seminoma.

Hosni A, Warde P, Jewett M, Bedard P, Hamilton R, Moore M, Nayan M, Huang R, Atenafu EG, O'Malley M, Sweet J, Chung P.

Clin Oncol (R Coll Radiol). 2016 Oct;28(10):648-54. doi: 10.1016/j.clon.2016.06.001. Epub 2016 Jun 20.

PMID:
27339401
35.

Estimating the costs of intensity-modulated and 3-dimensional conformal radiotherapy in Ontario.

Yong JH, McGowan T, Redmond-Misner R, Beca J, Warde P, Gutierrez E, Hoch JS.

Curr Oncol. 2016 Jun;23(3):e228-38. doi: 10.3747/co.23.2998. Epub 2016 Jun 9.

36.

PMH 9907: Long-term outcomes of a randomized phase 3 study of short-term bicalutamide hormone therapy and dose-escalated external-beam radiation therapy for localized prostate cancer.

McPartlin AJ, Glicksman R, Pintilie M, Tsuji D, Mok G, Bayley A, Chung P, Bristow RG, Gospodarowicz MK, Catton CN, Milosevic M, Warde PR.

Cancer. 2016 Aug 15;122(16):2595-603. doi: 10.1002/cncr.30093. Epub 2016 May 24.

37.

Omission of Breast Radiotherapy in Low-risk Luminal A Breast Cancer: Impact on Health Care Costs.

Han K, Yap ML, Yong JH, Mittmann N, Hoch JS, Fyles AW, Warde P, Gutierrez E, Lymberiou T, Foxcroft S, Liu FF.

Clin Oncol (R Coll Radiol). 2016 Sep;28(9):587-93. doi: 10.1016/j.clon.2016.04.003. Epub 2016 Apr 29.

PMID:
27139262
38.

The initiation of a multidisciplinary bladder cancer clinic and the uptake of neoadjuvant chemotherapy: A time-series analysis.

Nayan M, Bhindi B, Yu JL, Mamdani M, Fleshner NE, Hermanns T, Chung P, Milosevic M, Bristow R, Warde P, Hamilton RJ, Finelli A, Jewett MA, Zlotta AR, Sridhar SS, Kulkarni GS.

Can Urol Assoc J. 2016 Jan-Feb;10(1-2):25-30. doi: 10.5489/cuaj.3315.

39.

Lessons learned using an MRI-only workflow during high-dose-rate brachytherapy for prostate cancer.

Murgic J, Chung P, Berlin A, Bayley A, Warde P, Catton C, Simeonov A, Abed J, O'Leary G, Rink A, Ménard C.

Brachytherapy. 2016 Mar-Apr;15(2):147-55. doi: 10.1016/j.brachy.2015.12.004. Epub 2016 Jan 29.

PMID:
26832674
40.

Improving the Quality of Radiation Treatment for Patients in Ontario: Increasing Peer Review Activities on a Jurisdictional Level Using a Change Management Approach.

Reddeman L, Foxcroft S, Gutierrez E, Hart M, Lockhart E, Mendelsohn M, Ang M, Sharpe M, Warde P, Brundage M, Reddeman L, Foxcroft S, Gutierrez E, Hart M, Lockhart E, Mendelsohn M, Ang M, Sharpe M, Warde P, Brundage M.

J Oncol Pract. 2016 Jan;12(1):81-2, e61-70. doi: 10.1200/JOP.2015.006882.

PMID:
26759471
41.

Testicular cancer: germ cell tumours.

Chung P, Warde P.

BMJ Clin Evid. 2016 Jan 7;2016. pii: 1807. Review.

42.

"I sleep better at night:" How peer review of radiation treatment plans indirectly improves quality of care across radiation treatment programs.

Brundage MD, Hart M, O'Donnell J, Reddeman L, Gutierrez E, Foxcroft S, Warde P; Cancer Care Ontario Radiation Oncology Program Leads and the Pan-Canadian Peer Review Steering Committee.

Pract Radiat Oncol. 2017 Jul - Aug;7(4):281-288. doi: 10.1016/j.prro.2016.11.007. Epub 2016 Nov 24.

PMID:
28330746
43.

The experience of patients with early-stage testicular cancer during the transition from active treatment to follow-up surveillance.

Shen AH, Howell D, Edwards E, Warde P, Matthew A, Jones JM.

Urol Oncol. 2016 Apr;34(4):168.e11-20. doi: 10.1016/j.urolonc.2015.09.016. Epub 2015 Dec 18.

PMID:
26707612
44.

Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial.

Brundage M, Sydes MR, Parulekar WR, Warde P, Cowan R, Bezjak A, Kirkbride P, Parliament M, Moynihan C, Bahary JP, Parmar MK, Sanders K, Chen BE, Mason MD.

J Clin Oncol. 2015 Jul 1;33(19):2151-7. doi: 10.1200/JCO.2014.57.8724. Epub 2015 May 26.

45.

A phase II RCT and economic analysis of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy.

Alibhai SM, Santa Mina D, Ritvo P, Sabiston C, Krahn M, Tomlinson G, Matthew A, Segal R, Warde P, Durbano S, O'Neill M, Culos-Reed N.

BMC Cancer. 2015 Apr 25;15:312. doi: 10.1186/s12885-015-1316-8.

46.

Phase 2 trial of guideline-based postoperative image guided intensity modulated radiation therapy for prostate cancer: Toxicity, biochemical, and patient-reported health-related quality-of-life outcomes.

Berlin A, Cho E, Kong V, Howell KJ, Lao B, Craig T, Bayley A, Chung P, Gospodarowicz M, Warde P, Catton C, Bristow RG, Ménard C.

Pract Radiat Oncol. 2015 Sep-Oct;5(5):e473-e482. doi: 10.1016/j.prro.2015.02.015. Epub 2015 Apr 18.

PMID:
25899220
47.

Lymph Node Yield in Primary Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumors.

Nayan M, Jewett MA, Sweet J, Anson-Cartwright L, Bedard PL, Moore M, Chung P, Warde P, Hamilton RJ.

J Urol. 2015 Aug;194(2):386-91. doi: 10.1016/j.juro.2015.03.100. Epub 2015 Mar 28.

PMID:
25823792
48.

Long-term impact of androgen-deprivation therapy on physical function and quality of life.

Alibhai SM, Breunis H, Timilshina N, Naglie G, Tannock I, Krahn M, Warde P, Fleshner NE, Canning SD, Tomlinson G.

Cancer. 2015 Jul 15;121(14):2350-7. doi: 10.1002/cncr.29355. Epub 2015 Mar 24.

49.

Synergistic action of image-guided radiotherapy and androgen deprivation therapy.

Locke JA, Dal Pra A, Supiot S, Warde P, Bristow RG.

Nat Rev Urol. 2015 Apr;12(4):193-204. doi: 10.1038/nrurol.2015.50. Epub 2015 Mar 24. Review.

PMID:
25800395
50.

Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer.

Mason MD, Parulekar WR, Sydes MR, Brundage M, Kirkbride P, Gospodarowicz M, Cowan R, Kostashuk EC, Anderson J, Swanson G, Parmar MK, Hayter C, Jovic G, Hiltz A, Hetherington J, Sathya J, Barber JB, McKenzie M, El-Sharkawi S, Souhami L, Hardman PD, Chen BE, Warde P.

J Clin Oncol. 2015 Jul 1;33(19):2143-50. doi: 10.1200/JCO.2014.57.7510. Epub 2015 Feb 17.

Supplemental Content

Support Center